Natural-Substance-Based Nanomedicine for Ischemic Heart Disease

Nanoformulated natural substances are among the fields that are widely published on but rarely addressed. A recent review article in the Journal of Nanobiotechnology has summarized the state of research on ischemic heart disease, ranging from delivery systems to preclinical applications and the hurdles to clinical translation [1]. The most sobering statement in the paper appears in the chapter on these hurdles: In the field of clinical translation of nanomedicines, fewer than five percent of projects ever reach the clinical trial phase [1,2].